Synonyms: Mbi-4
Compound class:
Synthetic organic
Comment: This Merck BACE1 inhibitor, compound 9 (MBi-4), robustly lowers CSF and cortex Aβ40 in both rats and cynomolgus monkeys [1]. The clinical status is unclear with respect to verubecestat from Merck in Phase III for which it could be a back-up. More details in this blogpost.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Mandal M, Wu Y, Misiaszek J, Li G, Buevich A, Caldwell JP, Liu X, Mazzola RD, Orth P, Strickland C et al.. (2016)
Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. J Med Chem, 59 (7): 3231-48. [PMID:26937601] |